Journal
ONCOGENE
Volume 28, Issue 20, Pages 2119-2123Publisher
SPRINGERNATURE
DOI: 10.1038/onc.2009.73
Keywords
RAF1; BRAF; SRGAP3; fusion gene; pilocytic astrocytoma; MAPK
Funding
- Cancer Research UK
- Samantha Dickson Brain Tumour Trust
- CAMPOD
Ask authors/readers for more resources
Pilocytic astrocytomas (PAs), WHO malignancy grade I, are the most frequently occurring central nervous system tumour in 5- to 19-year-olds. Recent reports have highlighted the importance of MAPK pathway activation in PAs, particularly through a tandem duplication leading to an oncogenic BRAF fusion gene. Here, we report two alternative mechanisms resulting in MAPK activation in PAs. Firstly, in striking similarity to the common BRAF fusion, tandem duplication at 3p25 was observed, which produces an in-frame oncogenic fusion between SRGAP3 and RAF1. This fusion includes the Raf1 kinase domain, and shows elevated kinase activity when compared with wild-type Raf1. Secondly, a novel 3 bp insertion at codon 598 in BRAF mimics the hotspot V600E mutation to produce a transforming, constitutively active BRaf kinase. Although these two alterations are not common, they bring the number of cases with an identified 'hit' on the Ras/Raf-signalling pathway to 36 from our series of 44 (82%), confirming its central importance to the development of pilocytic astrocytomas. Oncogene (2009) 28, 2119-2123; doi:10.1038/onc.2009.73; published online 13 April 2009
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available